Shaping the Future of HHT Care
More information coming soon.
Phase 3 Study Enrollment is expected to begin in mid-2026.
HHT Study Updates
Vaderis - a biotechnology company focussing on treatment of rare and Orphan Diseases caused by Vascular Malformations
a biotechnology company focussing on treatment of rare and Orphan Diseases caused by Vascular Malformations